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Abstract
Background: Health-related quality of life is a topic of current interest. This paper considers a
randomized phase III study of radiation therapy with concurrent chemotherapy (docetaxel) versus
radiation therapy alone in non-small cell lung cancer, stage III A/B. Longitudinal data on quality of
life have been obtained through repeated administration of a multi-item questionnaire (EORTC
QLQ-C30) developed by the European Organisation for Research and Treatment of Cancer.
Missingness in the data is owing to patients having failed to complete the questionnaire at some of
the scheduled filling-in times.
Methods: We have analysed a monotone (in terms of missingness) subset of the data as regards
estimation of the mean score of a summary measure of self-reported quality of life in a hypothetical
drop-out-free population at different points in time. Missingness is a difficult issue of great
importance. We have therefore chosen to compare three different methods that are relatively easy
to implement: the linear-increments method, the inverse-probability-weighting method and the
Markov-process method. Single imputation has been applied in a supplementary analysis to fill in
for all the non-consecutive missing score values prior to the execution of the estimation procedure.
Results: For the response in focus, the observed mean score at a certain time is larger than the
estimated mean scores, which implies that the true mean score is easily overestimated unless the
missingness is appropriately adjusted for. Comparison of the treatment arms shows a significant
difference in mean score at the end of treatment.
Conclusion: Use of proper methodology developed for analysing data subject to missingness is
necessary to reduce potential estimation bias. The quality of life of patients receiving radiation
therapy with concurrent chemotherapy (docetaxel) appears somewhat worse than that of patients
receiving radiation therapy alone in the period during which treatment is given. The conclusions
are robust for the choice of statistical methods.
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Quality of life (QoL) is a rather complex multi-dimen-
sional concept that can be defined as the degree of well-
being felt by an individual [1]. It is commonly divided
into two different components: a physical component and
a psychological component. The former includes diet,
health, etc., while the latter involves different emotional
states such as worry, fear, sorrow and happiness. In health
care it is very important to consider QoL in the course of
a treatment evaluation. Since QoL is based on subjective
assessments, it is not easily quantifiable, as opposed to
more concrete measures like e.g. weight and blood pres-
sure.
Health-related QoL has been an area of research over the
past 20 years, and several international validated self-
report questionnaires have been developed in this regard
and used in longitudinal studies.
A longitudinal study involves time-discrete observation of
time-continuous processes, where measurements of the
variables of interest are taken at consecutive points in
time. These times are often represented by so-called study
waves; wave 1 represents the time at which the first set of
measurements is taken, wave 2 represents the time at
which the second set of measurements is taken, and so on.
A problem arises when study participants die, are lost to
follow-up or for other reasons fail to contribute all of the
planned sets of measurements. This resulting incomplete-
ness of data is a challenge to the analyst, and it may lead
to biased results if it is not taken into account in the statis-
tical analysis and adjusted for in an appropriate way. The
missingness is said to be of a monotone kind if a subject
that fails to contribute measurements at a certain study
wave, also fails to contribute measurements at all of the
subsequent waves. Otherwise, the missingness is said to
be of a non-monotone kind.
In this paper we consider a monotone (in terms of miss-
ingness) subset of longitudinal measurements of QoL.
The data are obtained from a randomized phase III study
of radiation therapy with concurrent chemotherapy versus
radiation therapy alone in non-small cell lung cancer
(NSCLC), stage III A/B. Location of the randomization
centre for this international multi-centre study was at The
Norwegian Radium Hospital in Oslo, Norway. The clini-
cal trial was approved by the Hospital Review Board, the
Regional Ethics Committee and the Norwegian Medicines
Agency. A total of 261 patients diagnosed with NSCLC,
stage III A (inoperable) or stage III B, were included in the
study between April 2000 and June 2006. Twelve of the
initially included patients were later excluded from the
study for not fulfilling the inclusion criteria. The final
study sample thus consisted of 249 patients (157 men and
92 women) from Denmark, Finland, Norway and Swe-
den. The study medication administration was divided
into two different treatment arms: arm A (study arm) and
arm B (standard arm). The former involved six weeks of
radiation therapy, given five days a week, combined with
weekly infusion of the cytotoxic drug docetaxel (Taxo-
tere®), whereas the latter involved solely six weeks of radi-
ation therapy. Upon inclusion, the patients were
independently randomized to one of the two treatment
arms; 119 (48%) of the patients were randomized to arm
A, and 130 (52%) of the patients were randomized to arm
B. Also, prior to inclusion of its first patient, each involved
centre had to decide whether two courses of induction
chemotherapy would be given before start of treatment, in
which case the same regimen would be used for all
patients included by that particular centre. Induction
chemotherapy involves initial treatment by giving the
patient standard chemotherapy before the start of radia-
tion therapy with the intention to reduce the volume of
the tumour (downstaging) in such a way that the radia-
tion area is reduced.
The primary objective of the study was to compare the sur-
vival time of radiation therapy combined with docetaxel
versus radiation therapy alone, and the secondary objec-
tive was to compare the time to progression and QoL in
the two treatment groups. Validated self-report, multi-
item questionnaires have been developed by the Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) in order to assess the QoL of cancer patients par-
ticipating in clinical trials. Translated versions of the
EORTC QLQ-C30 [2], supplemented by a lung cancer
module, were administrated to the patients at a pre-speci-
fied set of times during follow-up: immediately before
start of treatment (control week 0), at the end of treatment
(control week 6), six weeks after end of treatment (control
week 12), and then every 12 weeks until death, drop-out
or closure of the study in January 2009. The EORTC QLQ-
C30 includes 30 items in the form of questions regarding
a patient's symptoms, health and competency to perform
various daily life tasks, and in that way it covers and
reflects different generic aspects of QoL. Each item is
answered by circling the number corresponding to the
pre-coded response option that best applies. Nineteen of
the patients (9 in arm A and 10 in arm B) started induc-
tion therapy at the time of randomization. The timing of
the questionnaires for these patients differed from proto-
col, and hence, their answers have been discarded.
We have focused on item 30 in the EORTC QLQ-C30,
which is given by the following question: "How would
you rate your overall quality of life during the past week?".
This can be regarded as a summary measure of QoL, tak-
ing integer score values in the range from 1 to 7, where
scores of 1 and 7 correspond to 'very poor' and 'excellent',
respectively. That is, the higher the score value, the higherPage 2 of 14
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been to estimate the mean score of item 30 in a hypothet-
ical drop-out-free population in which every subject con-
tributes all planned sets of measurements. Ignoring
missingness present in the data might lead to biased mean
score estimates, and so we have made use of different
adjusting techniques. It is not obvious whether one
should adjust for all missing observations, including
those due to death, or whether one should only consider
surviving patients. The former corresponds to analysing
an immortal cohort, while the latter corresponds to analys-
ing a mortal cohort [3]. On the surface, the mortal cohort
analysis seems more reasonable, but in reality one may get
a false impression of the relationship between treatments.
For instance, it may be the case that one treatment
improves survival, but at the cost of QoL. Hence, the treat-
ment that is better in terms of survival may, precisely
because of this advantage, come out worse in terms of
QoL. Therefore, the immortal cohort analysis may be
worth considering. The procedure of correcting for all
missing observations, without regard to cause, can be
quite sensible in many circumstances and give a more fair
comparison of treatments. This will be our main approach
since we indeed wish to compare arm A and arm B as
regards QoL.
One further note should be made regarding adjusting for
mortality. In survival studies there is usually an amount of
censoring due to subjects entering the study late and thus
being under follow-up for just a short period of time. In
these cases one will not know when death takes place, and
so distinguishing between death and missingness due to
other causes may not be feasible. Hence, adjusting for all
missing observations may be the most clear-cut approach.
However, for the disease studied here, mortality is high,
and most patients have been followed until death. There-
fore, we have also performed a mortal cohort analysis,
where patients are removed from the study at their known
death times, and we have compared this with the other
analysis.
The employed methodology includes three methods that
rest on different assumptions. Merely using one method
could then result in wrong conclusions if the relevant
assumptions were not to be true. By using two or three
methods, the conclusions will be more certain and robust
when the respective results agree. The methodology has
been implemented using the programming language Mat-
lab® [4].
Methods
In this section we introduce the statistical framework used
for analysing longitudinal data subject to monotone miss-
ingness with regard to estimation of the mean of a time-
continuous, discrete-valued response variable.
Notation
Consider a longitudinal study of a time-continuous
response process , taking only discrete values, and some
time-continuous covariate processes , which can take
both discrete and continuous values. In accordance with
Diggle et al. [5] and Gunnes et al. [6], we refer to the var-
iable (t) as the hypothetical response at time t, that is, the
response that would have been recorded had the subject,
possibly contrary to fact, contributed a measurement at
this time. In the same way, we let (t) be the hypotheti-
cal covariates at time t. Measurements of the response and
covariates are scheduled for a pre-specified set of ordered
times t1,..., tτ, where τ is the total number of measurement
occasions. We assume that the data are subject to mono-
tone missingness, and the predictable time-continuous
response indicator process is denoted by R. The term 'pre-
dictable' means that the value of R(t) is known at time t-,
i.e. right before t. We set R(t) equal to 1 if the subject has
contributed all planned measurements of the response
and covariates up to, and including, time t. Otherwise, we
set R(t) equal to 0. Further, we write Y(t1),..., Y (tT) for the
observed responses, where T ≤ τ is the total number of
measurement sets the subject gives rise to. Correspond-
ingly, we write X(t1),..., X (tT) for the observed covariates.
The specification of the missingness and censoring
schemes presented below is based on the history of the
observed and unobserved processes. Following the nota-
tion of Gunnes et al. [6], the past history and strict past
history of the hypothetical time-continuous response
process  and covariate processes  at time t are written
 and
, respectively. In the same
way, R[t] denotes the past history of the time-continuous
response indicator process R at time t, and  R(t) denotes its
strict past. Note that since R is predictable, we have  R[t] =
R(t). If we restrict these histories to the scheduled measure-
ment times, we set  and
make an equivalent definition of . Further, we let
 and  denote the past history and strict past his-
tory, respectively, of the time-discrete observed response
and covariate processes, where
.
Y
X
Y
X
Y X
  G[ ] { ( ), ( ) : [ , ]}t X s Y s s t= ∈ 0
  G( ) { ( ), ( ) : [ , )}t X s Y s s t= ∈ 0
  G{ } { ( ), ( ) : ,..., }t kk X s Y s s t t= = 1
R{ }t k
G{ }t k G{ }t k−1
G{ } { ( ), ( ) : ,..., }t kk X s Y s s t t= = 1Page 3 of 14
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The methodology that we have made use of in our work is
based on some assumptions regarding the response indi-
cator process R.
The missingness completely at random (MCAR) condition
[[7], chapter 1.3] states that the response indicator process
is independent of the hypothetical response process 
and covariate processes :
In other words, knowledge of all realizations of the
response and covariate variables does not influence the
dropout probability.
When the missingness at random (MAR) condition [8] is
fulfilled, the response indicator process only depends on
the observed data:
This means that the probability of dropping out is unaf-
fected by response and covariate values that are not
observed. MAR is guaranteed by insisting that the
response indicator process depends solely on previously
observed responses and covariates. On the other hand, if
the response indicator process depends on unobserved
data, we have missingness not at random (MNAR).
The continuous-time independent censoring (CTIC) condi-
tion [9] can be defined as follows:
where  is shorthand for
. A sufficient, but not
necessary, condition for CTIC is 
for every time t. This allows R(t) to depend on any aspect
of the past of  and  but for the current infinitesimal
 and .
A stronger condition than CTIC is the discrete-time inde-
pendent censoring (DTIC) condition, which recognizes that
longitudinal data are measured in discrete time:
Thus, it places constraints on the expected value of the
increment  of the hypothetical
response. A sufficient condition for DTIC is
 for each time tk. This implies
that R(tk) may only depend on  and  until time tk-1,
and not on the interval (tk-1, tk) [6].
The DTIC condition may seem somewhat unrealistic, but
it corresponds to what can actually be observed. Clearly,
we cannot correct for the unobserved development within
an interval.
The linear-increments method
The linear-increments (LI) method postulates linear mod-
els for the increments of the hypothetical response process
 at different times. This was first proposed by Diggle et
al. [5] for continuous-valued response variables. Gunnes
et al. [6] discuss the LI technique for discrete-valued
response variables, for which the model at time tk is given
by
Here, the predictors (tk) are functions of the strict past
history , and β(tk) are the corresponding regression
functions. Following Diggle et al. [5] and Gunnes et al.
[6], we make the definitions (0) := 0 and (0) := 0. The
former leads to , where t1 > 0 is the time at
which the first set of measurements are taken.
Assuming DTIC, linear models are induced on the incre-
ments  of the observed data as well:
where . The regression functions β(tk)
are the same as for the hypothetical data, and they are esti-
mated for each time tk using ordinary least squares regres-
sion.
For every subject, the mean hypothetical response at time
tk is estimated by replacing the regression functions with
the ordinary least squares estimates  and then,
recursively, inserting previously obtained estimates into
Equation (5) and calculating the cumulative sum. Finally,
Y
X
[ | ] [ ].{ } { } { }R Rt t tτ τ τG = (1)
[ | ] [ | ].{ } { } { } { }R G R Gt t t tτ τ τ τ = (2)
E d E d( ( ) | , ) ( ( ) | ); ,( ) ( ) ( )   Y t Y t tt t tG R G= ≥ 0 (3)
( ) ( ( ) | )( )d E dt Y t t
−1  G
lim ( ( ) ( ) | )( )h t hh Y t Y t h↓
−
−
− −0
1E   G
[ | ] [ | ]( ) [ ] ( ) ( )R G R Gt t t t =
Y X
d Y t( ) d X t( )
E E( ( ) | , ) ( ( ) | ); ,..., .{ } ( ) { }Δ Δ   Y t Y t kk t t k tk k kG R G− −= =1 1 1 τ
(4)
Δ   Y t Y t Y tk k k( ) ( ) ( )= − −1
[ | ] [ | ]( ) { } ( ) { }R G R Gt t t tk k k k = −1
Y X
Y
E( ( ) | ) ( ) ( ); ,..., .{ }Δ   Y t V t t kk t k kkG − = =1 1β τ (5)
V
G{ }t k−1
Y V
Δ  Y t Y t( ) ( )1 1=
Δ ΔY t R t Y tk k k( ) ( ) ( )= 
E( ( ) | , ) ( ) ( ); ,..., ,{ } ( )ΔY t V t t kk t t k kk kG R− = =1 1β τ
(6)
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thetical response at time tk is given by the arithmetic aver-
age of all individual estimated mean hypothetical
responses. The detailed procedure is given by Gunnes et
al. [6].
The inverse-probability-weighting method
As the name suggests, the inverse-probability-weighting
(IPW) method involves weighting the observed responses
at a certain time by the inverse of the respective probabil-
ities of measurements being taken, and thus, creating a
pseudo-population where no data are missing. Following
Gunnes et al. [6], we let ρ(tk) = Pr{R(tk) = 1} be the prob-
ability that the subject contributes measurements of the
variables of interest at time tk, and we set ρ(t1) ≡ 1 for all
subjects. Further, we let 
be the conditional probability that the subject contributes
a set of measurements at time tk, given that a set of meas-
urements was contributed at tk-1. Under the assumption of
monotone missingness, the probability that the subject
contributes a set of measurements at time tk ≥ t2 is given by
If the MAR condition is fulfilled, the unknown condi-
tional probabilities  can be estimated in a
preliminary pooled logistic regression analysis [3,6]:
Here, the predictors Z(tk) are functions of the time tk and
, and α are the corresponding time-independent
regression coefficients. Subject-specific weights w(tk) are
found by taking the inverse of the respective estimated
measurement probabilities . We
have used "stabilized" weights [[10], page 562]
 to reduce the variability of the esti-
mates. Here,  is the estimated probability that a set
of measurements is taken at time tk, calculated by includ-
ing only baseline covariates in the logistic model given in
Equation (8).
Finally, the population mean  of the hypotheti-
cal response at time tk is estimated by a weighted arithme-
tic average of all observed responses:
where Yi(tk) denotes the observed response of subject i at
time tk, with corresponding weight wi(tk), and I(tk) is the
set of subjects of which measurements are taken at tk [6].
The Markov-process method
The Markov-process (MP) method [6] is based on an
assumption that the hypothetical response process  is a
Markov process with a finite state space  = {1,..., U},
where U ∈ Í is some natural number. Each state represents
a certain value of the response. Assuming monotone miss-
ingness, we let
  be the
number of observed subjects in state u at time tk-1 and in
state v at time tk. Here, Si(tk) denotes the state occupied,
that is, the response value attained, by subject i at time tk,
and I (tk) is the set of subjects of which measurements are
taken at tk.
If the DTIC condition is fulfilled, the discrete analogue
 of the time-continuous
Aalen-Johansen estimator [11] of the transition probabil-
ity matrix at time tk ≥ t2 is given by
where , and  equals the U-
dimensional identity matrix [6]. The estimated occupa-
tion probability of state v at time tk is
E( ( ))Y t k
π( ) Pr{ ( ) | ( ) }t R t R tk k k= = =−1 11
ρ π π τ( ) ( ) ( ); ,..., .t t t kk k= × × × =1 22 " (7)
π( | })t k kG {t −1
log
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π
π α τ
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tion of n subjects occupying state u at time t1. Finally, the
population mean  of the hypothetical response
at time tk is given by a weighted sum of the estimated state
occupation probabilities:
where cu denotes the value of the hypothetical response
corresponding to occupation of state u [6].
Single imputation
Subjects participating in longitudinal studies occasionally
fail to contribute measurements of the variables of interest
while under follow-up. This can result in a considerable
loss of information, especially when the employed meth-
odology is developed for analysing monotone (in terms
of missingness) subsets of the data. In order to be able to
utilize more of the available data, a feasible approach is to
use single imputation to fill in for all non-consecutive, i.e.
isolated, missing values that are directly preceded and suc-
ceeded by observed values. Thus, a new "artificial" and
more complete monotone (in terms of missingness) sub-
set of the data is created. (Multiple imputation has not
been used here since the added complexity was not
deemed necessary.)
In a supplementary analysis we have chosen to impute a
non-consecutive missing value at time tk by the arithmetic
average of the two corresponding adjacent observed val-
ues at times tk-1 and tk+1. That is, for instance, if a subject
contributes a measurement of value 4 at a certain time,
fails to contribute a measurement at the following time
and then contributes a measurement of value 6 at the next
time, the missing value in between the two observed ones
is imputed by (4 + 6)/2 = 5.
The MP method is currently developed only for integer-
valued responses or responses that can be cast in this
form. Since the non-consecutive missing values in some
cases may be imputed by decimal numbers, i.e. non-inte-
gers, we have not calculated the MP estimates when single
imputation has been applied prior to the data analysis.
During treatment and the first couple of weeks following
end of treatment, the scores reported by the patients ran-
domized to arm A changed considerably, and so, imputa-
tion of missing values in this period using the technique
described above would be inappropriate and might lead
to biased mean score estimates. Therefore, missing values
at the first three scheduled filling-in times of the EORTC
QLQ-C30, that is, control weeks 0, 6 and 12, have not
been imputed for either of the treatment arms.
Results
As previously mentioned, item 30 in the EORTC QLQ-
C30 has been the response in focus. This item deals with
the overall QoL of a patient during the past week. The
observation of the response process is discrete (in time),
corresponding to the filling in of the questionnaire.
It is reasonable to believe that the expected increment of a
discrete-valued response at time tk will depend on its pre-
vious value at time tk-1, as will the probability of contrib-
uting a response measurement at time tk. In addition, we
assume that sex, treatment arm and whether or not induc-
tion therapy was given will affect the response process as
well as the response indicator process. In consequence,
the following covariates have been included in the linear
regression model of the LI method: the previous score,
indicator for being a woman, indicator for being rand-
omized to arm A and indicator for having received induc-
tion chemotherapy. Further, the following covariates have
been included in the pooled logistic regression model of
the IPW method: indicators for the possible values of the
previous score, time, indicator for being a woman, indica-
tor for being randomized to arm A and indicator for hav-
ing received induction chemotherapy. (Note that in the
analysis where single imputation has been applied, the
previous score, instead of indicators for the possible val-
ues of the previous score, has been included in the pooled
logistic regression model of the IPW method. The reason
for this is that then the previous score value may actually
be a decimal number and not an integer in the range 1–7.)
Two corresponding immortal cohort analyses have been
performed using the three estimation methods. Single
imputation was not applied in the first analysis, whereas
in the second analysis it was applied. For comparison, a
mortal cohort analysis, without applying single imputa-
tion, has also been performed using the LI method.
Because of the assumption of monotone missingness,
only a selection of the score values in the original data set
are considered to be observed in a specific analysis, and
the remaining score values are thus regarded as missing.
All our analyses are restricted to 198 patients (98 in arm A
and 100 in arm B) whose respective score values at control
week 0, that is, immediately before start of treatment, are
available. Keep in mind that in the analysis where single
imputation has been applied, some of the observed score
values, with respect to monotone missingness, are actu-
ally missing values that have been imputed.
ˆ ( ) { ( ) }p t S t uu iin1 1
1
= =∑ 1
E( ( ))Y t k
E( ( )) ( ),Y t c p tk u u k
u
U
=
=
∑
1
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Table 1 presents the numbers of observed score values,
with respect to monotone missingness, for both treatment
arms at different control weeks. The corresponding num-
bers of missing score values are presented in Table 2.
Obviously, the numbers of observed score values decrease
over time as the patients fail to answer the current ques-
tion. In the same way, the numbers of missing score val-
ues increase over time. Figure 1 displays the mean score
estimates, plotted against time, for both treatment arms
when considering an immortal cohort. In the plot corre-
sponding to arm A, we notice a rapid decline in the curves
right after start of treatment. At control week 6, they reach
a low before increasing. This sudden dip at the end of
treatment is most likely due to some of the adverse effects
of chemotherapy, such as nausea and discomfort, which
generally lead to low score values. The curves fluctuate
somewhat after control week 24. In contrast, the curves in
the plot corresponding to arm B fall gradually. They begin
to rise again at control week 84. Figure 2 displays the LI
estimates of the mean score, plotted against time, for both
treatment arms when considering a mortal cohort. We
observe no important differences between the immortal
cohort analysis and the mortal cohort analysis as regards
estimation of the mean score using the LI method.
Figure 3 displays the empirical standard errors of the
mean score estimates (based on 1000 bootstrap samples),
plotted against time, for both treatment arms when con-
sidering an immortal cohort. As expected, the empirical
standard errors increase over time. The variability does
not seem to differ much between the three estimation
methods.
Figure 4 displays the differences in the mean score esti-
mates between arm A and arm B, plotted against time,
when considering an immortal cohort. The corresponding
95% percentile intervals (based on 1000 bootstrap sam-
ples) are also shown. The upper and lower percentile lim-
its lying on each side of the zero line corresponds to no
significant difference between the two treatment arms. At
control week 6, both percentile limits lie on the negative
side of the zero line in each of the plots. This indicates a
lower mean score in arm A compared to arm B at the end
Observed and estimated mean scores for an immortal cohort (without single imputation)Figure 1
Observed and estimated mean scores for an immortal cohort (without single imputation). The figure displays the 
observed and estimated mean scores for arm A (upper panel) and arm B (lower panel) when considering an immortal cohort. 
Single imputation has not been applied. The black solid-line curve corresponds to the arithmetic average of the observed score 
values, the blue dotted-line curve corresponds to the IPW method, the green dash-dotted-line curve corresponds to the LI 
method, and the red dashed-line curve corresponds to the MP method.
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BMC Medical Research Methodology 2009, 9:28 http://www.biomedcentral.com/1471-2288/9/28of treatment. In the plot corresponding to the IPW
method, the lower percentile limit lies just barely on the
positive side of the zero line at control week 72, which
indicates a possible higher mean score in arm A. However,
this is not supported by the results obtained from the
other two estimation methods.
With single imputation
Table 3 presents the numbers of observed score values,
with respect to monotone missingness, for both treatment
arms at different control weeks. The corresponding num-
bers of missing score values are presented in Table 4. By
comparing the numbers in Table 1 and Table 3, we see
that we get up to 4 and 6 more observed score values at a
given control week in arm A and arm B, respectively, when
single imputation is applied. Only a few of the score val-
ues that are gained have been imputed. The rest of them
are available score values that were considered to be miss-
ing in the first two analyses where single imputation was
not applied, but that now are regarded as observed
because of the filling in of non-consecutive missing values
preceding them.
Figure 5 displays the mean score estimates, plotted against
time, for both treatment arms when considering an
immortal cohort. By comparing the curves in Figure 1 and
Figure 5, we see that the application of single imputation
prior to the data analysis has not changed the observed
Observed and estimated mean scores for a mortal cohort (without single imputation)Figure 2
Observed and estimated mean scores for a mortal cohort (without single imputation). The figure displays the 
observed and estimated mean scores for arm A (upper panel) and arm B (lower panel) when considering a mortal cohort. Sin-
gle imputation has not been applied. The black solid-line curve corresponds to the arithmetic average of the observed score 
values, the magenta dotted-line curve corresponds to the LI method, and the green dash-dotted-line curve corresponds to the 
LI method when considering an immortal cohort (for comparison).
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Table 1: Numbers of observed score values (without single 
imputation).
Control week
0 6 12 24 36 48 60 72 84 96 108
Arm A 98 73 64 52 45 39 27 24 20 18 13
Arm B 100 81 73 67 62 47 31 26 19 14 12
The table presents the numbers of observed score values, with 
respect to monotone missingness, for arm A and arm B at different 
control weeks. Single imputation has not been applied.Page 8 of 14
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Table 2: Numbers of missing score values (without single imputation).
Control week
0 6 12 24 36 48 60 72 84 96 108
Arm A Death 0 3 9 23 30 37 48 56 61 66 72
Other causes 0 22 25 23 23 22 23 18 17 14 13
Arm B Death 0 0 3 13 20 29 42 50 59 62 69
Other causes 0 19 24 20 18 24 27 24 22 24 19
The table presents the numbers of missing score values, with respect to monotone missingness, due to death and other causes for arm A and arm 
B at different control weeks. Single imputation has not been applied.
Empirical standard errors of the estimated mean scores for an immortal cohort (without single imputation)Figu e 3
Empirical standard errors of the estimated mean scores for an immortal cohort (without single imputation). 
The figure displays the empirical standard errors of the estimated mean scores (based on 1000 bootstrap samples) for arm A 
(upper panel) and arm B (lower panel) when considering an immortal cohort. Single imputation has not been applied. The blue 
dotted-line curve corresponds to the IPW method, the green dash-dotted-line curve corresponds to the LI method, and the 
red dashed-line curve corresponds to the MP method.
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Differences in the observed and estimated mean scores for an immortal cohort (without single imputation)Figu  4
Differences in the observed and estimated mean scores for an immortal cohort (without single imputation). 
The figure displays the differences in the observed and estimated mean scores between arm A and arm B for the arithmetic 
average of the observed score values (upper left panel), the IPW method (upper right panel), the LI method (lower left panel) 
and the MP method (lower right panel) when considering an immortal cohort. Single imputation has not been applied. The 
black solid-line curve corresponds to the estimated differences, the black dashed-line curves correspond to the upper and 
lower limits of the 95% percentile interval (based on 1000 bootstrap samples), and the black dotted-line curve corresponds to 
the zero line.
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Table 3: Numbers of observed score values (with single imputation).
Control week
0 6 12 24 36 48 60 72 84 96 108
Arm A Non-imputed 98 73 64 52 48 42 28 27 22 20 15
Imputed 0 0 0 3 1 0 2 0 1 0 0
Arm B Non-imputed 100 81 73 67 62 47 34 32 24 19 15
Imputed 0 0 0 0 0 3 3 0 0 0 1
The table presents the numbers of observed score values, with respect to monotone missingness, for arm A and arm B at different control weeks. 
Single imputation has been applied.
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Table 4: Numbers of missing score values (with single imputation).
Control week
0 6 12 24 36 48 60 72 84 96 108
Arm A Death 0 3 9 23 30 37 48 56 61 66 72
Other causes 0 22 25 20 19 19 20 15 14 12 11
Arm B Death 0 0 3 13 20 29 42 50 59 62 69
Other causes 0 19 24 20 18 21 21 18 17 19 15
The table presents the numbers of missing score values, with respect to monotone missingness, due to death and other causes for arm A and arm 
B at different control weeks. Single imputation has been applied.
Observed and estimated mean scores for an immortal cohort (with single imputation)Figure 5
Observed and estimated mean scores for an immortal cohort (with single imputation). The figure displays the 
observed and estimated mean scores for arm A (upper panel) and arm B (lower panel) when considering an immortal cohort. 
Single imputation has been applied. The black solid-line curve corresponds to the arithmetic average of the observed score val-
ues, the blue dotted-line curve corresponds to the IPW method, and the green dash-dotted-line curve corresponds to the LI 
method.
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BMC Medical Research Methodology 2009, 9:28 http://www.biomedcentral.com/1471-2288/9/28and estimated mean scores very much. Figure 6 displays
the empirical standard errors of the mean score estimates
(based on 1000 bootstrap samples), plotted against time,
for both treatment arms when considering an immortal
cohort. It is evident that single imputation reduces the var-
iability of the estimates.
Figure 7 displays the differences in the mean score esti-
mates between arm A and arm B, plotted against time,
when considering an immortal cohort. The corresponding
95% percentile intervals (based on 1000 bootstrap sam-
ples) are also shown. The curve patterns resemble the ones
displayed in Figure 4.
Discussion
Results from the data analyses suggest that the true mean
score might be overestimated by using the observed mean
score, which equals the arithmetic average of the observed
score values at a given control week. The most likely rea-
son for this is that the worst patients, that is, the patients
with the lowest score values, fail to complete the question-
naire. Thus, higher score values tend to predominate in
the data. The initial and sudden drop in the curves of the
mean score estimates in the plots corresponding to arm A
is in accordance with what might have been expected; the
patients in arm A, who received both radiation therapy
and chemotherapy, experienced an immediate reduction
in mean score, as opposed to the patients in arm B, who
received only radiation therapy. However, the difference
between the two treatment arms with respect to the mean
score seems to diminish over time.
The application of single imputation did not alter the
mean score estimates considerably, but the numbers of
extra observed score values were indeed quite low. It did,
however, lower the empirical standard errors of the mean
score estimates. In other words, we gain precision from
using single imputation, and this makes our estimates
more reliable.
The MP method is certainly the easiest one to implement
among the three estimation methods. However, this
method, unlike the other two methods, is limited to han-
dle only discrete-valued responses. Further, the IPW
method may give more variable estimates and thus less
precision [12]. Therefore, we recommend using the LI
Empirical standard errors of the estimated mean scores for an immortal cohort (with single imputation)Figu e 6
Empirical standard errors of the estimated mean scores for an immortal cohort (with single imputation). The 
figure displays the empirical standard errors of the estimated mean scores (based on 1000 bootstrap samples) for arm A 
(upper panel) and arm B (lower panel) when considering an immortal cohort. Single imputation has been applied. The blue dot-
ted-line curve corresponds to the IPW method, and the green dash-dotted-line curve corresponds to the LI method.
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BMC Medical Research Methodology 2009, 9:28 http://www.biomedcentral.com/1471-2288/9/28method in practice when appropriate. This is a good
method that is relatively easy to implement. The Matlab®
code for the implementation of the methodology consid-
ered in this paper is available and can be obtained by con-
tacting the corresponding author.
Conclusion
Health-related QoL is an important research field of cur-
rent interest. In medical settings we believe that it is cru-
cial to consider QoL when treatments are being evaluated.
The obtained results from the data analyses correspond-
ing to the three estimation methods agree with one
another. Within each treatment arm, the estimated mean
scores of self-reported QoL are adjusted downwards com-
pared to the observed mean score. There are significant
differences in the estimated mean scores of self-reported
QoL between arm A and arm B at the end of treatment.
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